Chapter 164: No Miracle Language
Sterling's first reform campaign promised to change everything.
The slogan appeared on a black screen above the restored laboratory name.
A NEW ERA. A PLATFORM THAT CHANGES EVERYTHING.
The communications team called it hopeful.
I called it unsupported.
The old authorization had been revoked. The Trust license to Sterling remained suspended. No new FBRA approval existed. Process reform did not transform research uncertainty into a result.
The communications brief cited the shareholder vote as if governance approval were scientific evidence. The two events belonged on separate pages.
"It does not say cure," the marketing director said.
"It implies certainty the record does not support."
The team presented alternatives.
RESEARCH REBORN.
THE FUTURE RESTORED.
HELENA'S PROMISE FULFILLED.
I rejected all three.
I asked which authorized project each slogan described. The room had no answer. A future application was not a current study, and a historical platform was not a promised product.
Helena had not promised an outcome. Sterling had no right to use her death as a guarantee.
Mara asked communications to separate governance from science. The company could announce verified reforms: independent reporting, recurring audits, attribution rules, employee appeal, and patient governance. It could not claim those reforms made a research platform successful.
Each governance claim also needed a status. Approved was different from implemented. Implemented was different from independently tested. The public page would show all three.
The scientific-review panel drafted a plain statement.
Sterling Biotech has changed its governance and record systems. The underlying platform remains under independent ownership and review. The old trial authorization has been revoked. Any future research would require new, separate permissions and would retain unknown limits.
The sentence did not sound like a launch.
It sounded true.
The marketing director warned that investors would hear weakness.
"Uncertainty is not weakness when uncertainty is the fact," Mara said.
She asked finance to record the cost of delay separately. Honest language would not become an invisible expense executives later blamed on reform.
The proposed campaign was delayed for forty-eight hours while the outside auditor tested every claim. No executive could approve a scientific statement alone.
The auditor found another problem.
A timeline said Sterling had "restored full platform rights." The company had restored no such rights. The Trust remained owner, Sterling's license remained suspended, and the revoked authorization could not restart.
The line disappeared with a visible correction reason.
The correction log preserved who drafted it, who flagged it, and why it changed. Training and review came before individual accountability for language inherited from the old campaign process.
Julian's independent Mercer team received no advance copy. My nonoperating adviser status at Mercer gave me no channel to coordinate a competing message.
Celeste called the delay proof that I did not know how to lead a public company.
Perhaps certainty would have produced a faster campaign.
It had also helped produce the record we spent nine months correcting.
The revised public page led with the five governance changes and linked to their audit status. Its research section contained only current authority and limits.
The first three reforms showed implemented. Employee appeal showed active rollout. The patient council showed approved design, not completed membership.
No participant image appeared.
Leah's council design was described without her name.
Mina's testimony was not converted into a redemption quote.
The local result was delay.
Sterling missed a media window and one investor conference panel. The cost entered the communications report rather than being hidden.
The team rescheduled only after the external reviewer signed the claim sheet. No executive, founder, or chair could override that gate.
Employees still received the corrected campaign internally.
One scientist wrote that the language felt smaller.
"It is," I answered. "The claim should be no larger than the evidence."
Another employee asked whether small language meant Sterling lacked confidence.
"It means confidence does not replace permission or data," the scientific panel answered.
At the next board meeting, the marketing director presented performance data showing fewer clicks than the miracle draft predicted.
The board did not order the old slogan restored.
For once, Sterling accepted less attention as the price of not promising what it did not know.